Adverse Event reporting can be found below.
Our Portfolio
Thornton and Ross are committed to providing cost-effective treatment for the NHS and pharmacies in the UK. As part of the STADA Group, Thornton and Ross are constantly adding to their existing product portfolio and continue to be seen as global leaders of specialty, biosimilar and generic products.
NICE guideline updated1 Recommended in the 2025 KDIGO Guidelines3
Kinpeygo®▼ 4mg (modified-release hard capsules budesonide)
NICE recommends Kinpeygo® as an option in adults with UPCR ≥ 90 mg/mmol or protein excretion of ≥ 1.0 g/day.1 NICE and KDIGO recommend disease-modifying Kinpeygo® for treatment of IgA nephropathy (IgAN) alongside optimised standard care.1,3 Kinpeygo® is indicated for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥ 1.0 g/day (or UPCR ≥ 0.8 g/g, equivalent to ≥ 90 mg/mmol).1,2
Prescribing information is available here. References: 1. NICE. Technology appraisal guidance TA1128: Targeted-release budesonide for treating primary IgA nephropathy. Available at: https://www.nice.org.uk/guidance/ta1128. Last accessed: March 2026; 2. Kinpeygo® SmPC. Available at: www.medicines.org.uk/emc/product/15393/smpc. Last accessed: March 2026; 3. KDIGO. Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV). Available at: https://kdigo.org/guidelines/iga-nephropathy/. Last accessed: March 2026.
Uzpruvo®▼ (ustekinumab)
Uzpruvo is STADA’s ustekinumab biosimilar and offers a cost-effective alternative to the reference product.1-3 Uzpruvo is used for the treatment of moderate to severe Crohn’s disease in adults, moderate to severe active ulcerative colitis in adults, moderate to severe plaque psoriasis in adults, moderate to severe paediatric plaque psoriasis and psoriatic arthritis in adults.1
Prescribing information is available here. References: 1. Uzpruvo SmPC. Available at: https://www.medicines.org.uk/emc/search?q=Uzpruvo. Last accessed: March 2026. 2. Cost of Uzpruvo taken from NHS DM+D. Available at: https://dmd-browser.nhsbsa.nhs.uk/search/results?ampName=uzpruvo. Last accessed: March 2026. 3. Cost of reference product (Stelara) taken from NHS DM+D. Available at: https://dmd-browser.nhsbsa.nhs.uk/search/results?ampName=stelara. Last accessed: March 2026.
Movymia®▼ (teriparatide)
Movymia® is a teriparatide biosimilar from STADA UK. Movymia® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.1
Prescribing information is available here. References: 1. Movymia 20 micrograms/80 microliters solution for injection SmPC. Available at: https://www.medicines.org.uk/emc/product/10780. Last accessed: March 2026.
Information
For SmPC follow the links which will take you to the Electronic Medicines Compendium (emc) website which is a non-Thornton & Ross website. https://www.medicines.org.uk/emc/.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing [email protected] or by calling 01484 848164.
UK-MULT-113(5) | March 2026
